Livagen is a tetrapeptide bioregulator targeting liver (hepatic) tissue — one of the most metabolically central organs in the body and the primary site of detoxification, protein synthesis, lipid metabolism, glucose homeostasis, and coagulation factor production. Developed by Dr. Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, Livagen's tissue-specific peptide sequence activates the gene expression programs of hepatocytes and hepatic stellate cells that are progressively silenced by age-related epigenetic changes, chronic metabolic burden, and toxic exposures.

The liver's metabolic functions are so broad that hepatic aging has systemic consequences: deteriorating lipid metabolism (rising LDL, dyslipidemia), reduced synthesis of carrier proteins, coagulation factors, and albumin, impaired phase I and II detoxification (reduced cytochrome P450 activity), declining gluconeogenic capacity, and impaired hepatic clearance of metabolic waste products. These changes accumulate silently over decades before they manifest as detectable dysfunction — making epigenetic maintenance of hepatocyte function a compelling preventive strategy.

Livagen operates through the characteristic Khavinson mechanism: the tetrapeptide penetrates hepatocyte nuclei and binds to histone-DNA complexes in hepatic chromatin, reactivating transcription of hepatocyte-specific genes whose promoters have been hypermethylated or compacted by aging. Target genes include those encoding detoxification enzymes (CYP450 family, GST, UGT), lipid metabolizing enzymes, glucokinase and other glycolytic enzymes, albumin, coagulation factors, and anti-inflammatory mediators produced by the liver. The restoration of expression in these functional gene categories translates directly to restored metabolic capacity.

A particularly significant mechanism attributed to Livagen is its effect on chromatin decondensation. Livagen has been shown to increase the accessibility of condensed heterochromatin in hepatocytes — "opening up" epigenetically silenced genomic regions to allow transcriptional activity that aging has progressively restricted. This chromatin remodeling effect is not specific to single genes but operates at the level of broader genomic accessibility, making Livagen one of the more broadly epigenetically active peptides in the Khavinson series. This mechanism also underpins observed effects on cellular longevity markers.

In experimental systems, Livagen treatment of hepatocyte cultures and aging animal liver tissue produces measurable increases in hepatic metabolic enzyme activity, improved detoxification capacity (measured by clearance rates of test substrates), and better preservation of hepatic histological architecture. In aged animals, Livagen treatment reduced markers of hepatic aging and improved liver function parameters — with effects persisting well beyond the treatment period, consistent with epigenetic restoration rather than pharmacological support.

Beyond pure hepatic function, Livagen has demonstrated effects on immune modulation. The liver is a major immune regulatory organ — it produces acute phase reactants, tolerizes the immune system to dietary antigens via hepatic tolerogenic mechanisms, and houses a large population of resident macrophages (Kupffer cells). Livagen's hepatic epigenetic restoration influences these immune functions as well, contributing to the normalized inflammatory signaling observed in aged animal models following treatment.

Protocol: 1–2mg/day for 10 consecutive days, administered subcutaneously or intranasally, repeated 2–4 times per year. Combines synergistically with Ovagen (GI mucosa/liver bioregulator) and Pancragen (pancreatic bioregulator) for comprehensive hepato-gastrointestinal aging support.